Recommendations for Fully Vaccinated People
COVID-19 Homepage
Create a COVID-19 Action Plan
Interpretive Summary for February 10, 2023
Create a COVID-19 Action Plan
Since the beginning of the COVID-19 pandemic almost three years ago, we have known that some people who are immunocompromised (have a weakened immune system) are more likely to get sick with COVID-19 or be sick for a longer period. Evusheld, a pre-exposure preventative treatment, gave people with weakened immune systems extra protection against severe outcomes from COVID-19. However, on January 26, 2023, the U.S. Food and Drug Administration announcedExternal that Evusheld is not currently authorized for emergency use in the United States because it is unlikely to be active against the majority of circulating SARS-CoV-2 variants at this time.
With this change, CDC encourages people who have weakened immune systems (or who live with someone who does) to create a COVID-19 action plan (en español). Vaccination is the first line of protection to prevent serious illness, hospitalization, and death from COVID-19. People who are immunocompromised might not have as strong of an immune response to COVID-19 vaccines, but staying up to date with COVID-19 vaccines will help. Everyone who is eligible should stay up to date with COVID-19 vaccines and boosters for the added protection.
If you have a weakened immune system and test positive for SARS-COV-2 or have a known exposure, talk to a doctor to get antiviral treatment as soon as possible. You should also consider prevention measures such as wearing a comfortable, well-fitting respirator or mask, maintaining physical distance (more than 6 feet) from others, improving indoor ventilation, and washing your hands often. CDC’s People Who Are Immunocompromised and Steps for People with Weakened Immune Systems to Stay Safe from COVID-19 pages have more information on how to protect yourself from COVID-19.
Note to Readers: CDC will not publish the COVID Data Tracker Weekly Review on Friday, February 17, 2023. Publication will resume on Friday, February 24, 2023.
- Updated booster dose data for children under age 5 years were added to COVID Data Tracker’s Maps of Vaccination Coverage by Age and Sex over Time tab.
- COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022
COVID-19 Community Levels*
As of February 9, 2023, there are 91 (2.8%) counties, districts, or territories with a high COVID-19 Community Level, 715 (22.2%) with a medium Community Level, and 2,407 (74.8%) with a low Community Level. Compared with last week, the number of counties, districts, or territories in the high level decreased by 1.2%, in the medium level decreased by 3.2%, and in the low level increased by 4.3%. Overall, 47 out of 52 jurisdictions** had high- or medium-level counties this week. Arizona, District of Columbia, Hawaii, New Hampshire, and Utah are the only jurisdictions to have all counties at low Community Levels.
To check your COVID-19 Community Level, visit COVID Data Tracker. To learn which prevention measures are recommended based on your COVID-19 Community Level, visit COVID-19 by County.
*CDC recommends use of COVID-19 Community Levels to determine the impact of COVID-19 on communities and to take action. CDC also provides Community Transmission Levels to describe the amount of COVID-19 spread within each county. Healthcare facilities use Community Transmission Levels to determine infection control interventions.
**Includes the 50 states, the District of Columbia, and Puerto Rico.
Reported Cases
As of February 8, 2023, the current 7-day average of weekly new cases (40,404) decreased 1.0% compared with the previous 7-day average (40,815). A total of 102,736,819 COVID-19 cases have been reported in the United States as of February 8, 2023.
102,736,819
Total Cases Reported
40,404
Current 7-Day Average*
40,815
Previous 7-Day Average
-1.0%
Change in 7-Day Average since Previous Period
*Historical cases are excluded from weekly new cases and 7-day average calculations until they are incorporated into the dataset for the applicable date. Of 25,904 historical cases reported retroactively, 4,507 were reported in the current week and none in the prior week.
Weekly Trends in COVID-19 Cases in the United States Reported to CDC
COVID-19 Variants
CDC Nowcast projections* for the week ending February 11, 2023, estimate the proportion of these lineages designated as Omicron with estimates above 1%: XBB.1.5, BQ.1.1, BQ.1, XBB, and CH.1.1.
XBB.1.5 is projected to be at approximately 74.7% (95% PI 67.0-81.2%). XBB.1.5 is expected to have at least one sublineage (XBB.1.5.1) that may be broken out by CDT next week, when it is expected to be above 1% weighted estimates.
The second most prevalent lineage is BQ.1.1, projected to be at approximately 15.3% (95% PI 11.4-20.2%).
BQ.1, XBB, CH.1.1, and BN.1 are all projected to be between 1% and 5.1% of circulating lineages.
XBB.1.5 is growing in proportion in all HHS regions. All other virus lineages are predicted to have very slow or no growth in proportion.
See COVID Data Tracker for the proportions of all relevant lineages currently circulating.
*CDC uses Nowcast projections to predict current variant proportions circulating in the United States. The median time from specimen collection to sequence data reporting is about 3 weeks. As a result, weighted estimates for the most recent few weeks may be unstable or unavailable. View Nowcast estimates on CDC’s COVID Data Tracker website on the Variant Proportions page.
Vaccinations
As of February 8, 2023, 670.3 million vaccine doses have been administered in the United States. Overall, about 229.8 million people, or 69.2% of the total U.S. population, have completed a primary series.* About 52.5 million people, or 15.8% of the U.S. population, have received an updated booster dose.
670,306,507
Vaccine Doses Administered
52,871,702
Updated Booster Doses Administered**
229,820,324
People who have completed a primary series* (69.2% of the U.S. population)
52,499,720
People who have received an updated booster (15.8% of the eligible U.S. population)
+0.0
Percentage point change from last week
+0.1
Percentage point change from last week
*Represents the number of people who have received the second dose in a two-dose COVID-19 vaccine series (such as the Pfizer-BioNTech, Moderna, or Novavax vaccines) or one dose of the single-shot Johnson & Johnson’s Janssen vaccine.
**The number of updated booster doses administered is larger than the number of people who have received an updated booster because one person may receive more than one booster dose.
Daily Change in the Total Number of Administered COVID-19 Vaccine Doses Reported to CDC by the Date of Administration, United States
7-Day moving average
COVID-19 Updated Booster Dose Administration, United States
5,924,203
Total New Admissions
3,665
Current 7-Day Average
3,907
Prior 7-Day Average
-6.2%
Change in 7-Day Average
The start of consistent reporting of hospital admissions data was August 1, 2020.
Daily Trends in Number of New COVID-19 Hospital Admissions in the United States
New admissions are pulled from a 10 am EDT snapshot of the HHS Unified Hospital Data – Analytic Dataset. Due to potential reporting delays, data from the most recent 7 days, as noted in the figure above with the grey bar, should be interpreted with caution. Small shifts in historic data may also occur due to changes in the Centers for Medicare & Medicaid Services (CMS) Provider of Services file, which is used to identify the cohort of included hospitals.
RESP-NET: COVID-19 Associated Hospitalization Rates among Adults Ages 65 Years and Older
CDC’s Respiratory Virus Hospitalization Surveillance Network (RESP-NET) shows that overall weekly rates of COVID-19-associated hospitalizations have declined for all age groups from a peak in December 2022. However, adults ages 65 years and older continue to be disproportionately impacted by COVID-19 associated hospitalizations, accounting for nearly half of all cases since October 1, 2022, with a weekly rate of 27.4 per 100,000 population for the week ending January 21, 2023.
Weekly Rates of Respiratory Virus-Associated Hospitalizations among Adults Ages 65 Years and Older
The dashed lines for the current season indicate potential reporting delays and interpretation of trends should exclude data from recent weeks. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a RESP-NET platform, is an additional source for hospitalization data collected through a network of more than 250 acute-care hospitals in 13 states (representing ~10% of the U.S. population). Detailed data on patient demographics, including race and ethnicity, underlying medical conditions, medical interventions, and clinical outcomes, are collected using a standardized case reporting form.
Deaths
The current 7-day average of new deaths (453) decreased 9.7% compared with the previous 7-day average (502). As of February 8, 2023, a total of 1,110,364 COVID-19 deaths have been reported in the United States.
1,110,364
Total Deaths Reported
453
Current 7-Day Average*
502
Prior 7-Day Average
-9.7%
Change in 7-Day Average Since Prior Period
*Historical deaths are excluded from the weekly new deaths and 7-day average calculations until they are incorporated into the dataset by their applicable date. Of 3,838 historical deaths reported retroactively, none were reported in the current week and none were reported in the prior week.
Testing
The percentage of COVID-19 NAATs (nucleic acid amplification tests)* that are positive is increasing in comparison to the previous week. The 7-day average of percent positivity from NAATs is now 10.6%. The 7-day average number of tests reported for January 27–February 2, 2023, was 257,631, down 17.7% from 313,044 for the prior 7 days.
1,014,370,606
Total Tests Reported
257,631
7-Day Average Tests Reported
10.6%
7-Day Average % Positivity
10.2%
Previous 7-Day Average % Positivity
+0.44
Percentage point change in 7-Day Average % Positivity since Prior Week
*Test for SARS-CoV-2, the virus that causes COVID-19
COVID-19 NAAT Laboratory Test 7-day Percent Positivity by State/Territory
Wastewater Surveillance
COVID Data Tracker’s Wastewater Surveillance tab tracks levels, changes, and detections of SARS-CoV-2* viral RNA in wastewater at over 1,200 testing sites across the country.
Currently, about 65% of sites across the country are reporting moderate to high SARS-CoV-2 levels in wastewater. About 29% of sites reporting wastewater data are currently seeing some of the highest levels for those sites since December 1, 2021. About 41% of sites are experiencing a decrease in SARS-CoV-2 levels, and about 49% are reporting an increase.
For more information on how to use wastewater data, visit CDC’s wastewater surveillance website.
*The virus that causes COVID-19
SARS-CoV-2 Levels in Wastewater by Site
0% denotes that levels are the lowest they have been at the site; 100% denotes that levels are the highest they have been at the site.